Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott Humira trials yield new RA insights

Abbott Humira trials yield new RA insights

11th November 2010

Abbott has reported data from two recent studies of its rheumatoid arthritis (RA) treatment Humira, which offers new insight into the functioning of the disease.

Pooled analysis of two pivotal trials of the drug showed that inflammation was more strongly correlated to deteriorating physical function among patients suffering from RA for less than three years than those with long-standing cases of the disease.

In contrast, long-term sufferers were more likely to see a correlation between structural damage and worsening physical function than those with early RA.

Dr Martin Bergman, clinical associate professor of medicine at the Drexel University College of Medicine and lead investigator in the studies, said the information can provide new understanding of how the nature of RA changes over time.

Abbott's vice-president for global pharmaceutical development Dr Eugene Sun added: "This data and analysis provides additional insights into RA which we hope will inform better patient care in the future."

Last month, the pharmaceutical company published its third quarter financial results, reporting an 11.8 percent year-over-year growth in worldwide sales.ADNFCR-8000103-ID-800229831-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.